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Abstract
Introduction: Henoch-Schönlein purpura is a small-vessel systemic vasculitis. Although its exact pathophysiology
remains unknown, Henoch-Schönlein purpura has been reported in association with various medical conditions
including hypersensitivity. We report the case of a patient with vancomycin-induced Henoch-Schönlein purpura.
Case presentation: A 42-year-old Caucasian man who had previously undergone a heart transplant was
diagnosed as having an intra-abdominal abscess after he underwent a Hartmann procedure. At 15 days after
initiation of antibiotic therapy including vancomycin, he developed a purpuric rash of the lower limbs, arthralgia,
and macroscopic hematuria. At that time, our patient was already on hemodialysis for end-stage renal disease.
Henoch-Schönlein purpura was diagnosed. After a second 15-day course of vancomycin, a second flare of Henoch-
Schönlein purpura occurred. Skin biopsies showed leucocytoclastic vasculitis with IgA deposits and eosinophils in
the peri-capillary inflammatory infiltrate, suggesting an allergic mechanism. After vancomycin was stopped, we did
not observe any further flares. Only five cases of isolated cutaneous vasculitis, one case of lupus-like syndrome and
one case of Henoch-Schönlein purpura after vancomycin treatment have been described to date in the literature.
Conclusions: Clinicians should be aware that systemic vasculitis can be induced by some treatments. Vancomycin
is a widely prescribed antibiotic. Occurrence of rare but serious Henoch-Schönlein purpura associated with
vancomycin requires its prompt discontinuation.
Introduction
Henoch-Schönlein purpura (HSP) is a small-vessel sys-
temic vasculitis. Its usual clinical presentation includes
vascular purpura, abdominal pain, arthralgia, and glo-
merulonephritis. Although its exact pathophysiology
remains unknown, HSP has been reported in association
with various medical conditions such as cancer, blunt
trauma, monoclonal IgA gammopathy, as well as in
patients with Wiskott-Aldrich syndrome, chronic alco-
holic liver disease, or a1-anti-trypsin deficiency [1]. HSP
has also been described in association with hypersensi-
tivity. Several drugs, such as ciprofloxacin, acetylsalicylic
acid, carbidopa/levodopa, cocaine, acetyl cholinesterase
inhibitors, carbamazepine and streptokinase have been
involved in the induction of HSP [1]. Here, we report
w h a ti st ot h eb e s to fo u rk n o w l e d g eo n l yt h es e c o n d
case of vancomycin-induced HSP.
Case presentation
A 42-year-old Caucasian man was referred to our
Nephrology Department. He presented with acute renal
failure linked to severe dehydration secondary to diar-
rhea that had lasted a week. He was known to have
end-stage renal disease secondary to nephrotoxicity
from calcineurin inhibitors administered over 15 years
as part of his heart transplant anti-graft rejection regi-
men, but had not started hemodialysis yet. His estimated
glomerular filtration rate (GFR), using Modification of
Diet in Renal Disease (MDRD) calculation, was 16.8
mL/minute/1.73 m
2 before admission, and he had only
mild proteinuria (0.56 g/24 hours) and no hematuria.
On admission, his clinical and specifically his abdom-
inal examinations were unremarkable except for the pre-
sence of non-hemorrhagic and non-mucoid diarrhea
associated with fever. Community-acquired infectious
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any medium, provided the original work is properly cited.gastroenteritis was suspected. Our patient’s medical his-
tory revealed he had been diagnosed as having a trans-
position of the great arteries that led to an initially
successful heart transplantation 15 years ago, before the
occurrence of chronic cardiac transplant rejection. As a
former smoker, he had also had an isolated ischemic
stroke five years ago, but had no history of allergies or
anaphylaxis. A recent echocardiograph showed conges-
tive heart failure, with, a left ventricular ejection fraction
of 30% and pulmonary hypertension. His immunosup-
pressive regimen included cyclosporin (45 mg twice a
day) and prednisone (5 mg/day). He was given intrave-
nous antibiotic therapy including ceftriaxone (1 g/day)
and oral ciprofloxacin (500 mg/day).
Because he presented with symptoms of heart failure
following rehydration, as well as no improvement of his
renal function, intermittent hemodialysis was started on
day five after admission after the placement of a tem-
porary jugular catheter. By day nine, because of persis-
tent sepsis and diarrhea despite the antibiotic therapy,
an abdominal computed tomography (CT) scan was per-
formed and our patient was diagnosed as having ster-
coral peritonitis secondary to a colonic diverticular
perforation. Bacteroides fragilis was identified in blood
cultures. A Hartmann surgical procedure was performed
and the antibiotic therapy was switched to piperacillin/
tazobactam (4 g twice a day) (Figure 1).
By day 24 after admission, our patient showed clinical
improvement. He had no further fever or diarrhea, and
his biological test results had normalized, so piperacil-
lin/tazobactam was stopped. On day 27, his fever
recurred. A second abdominal CT scan showed an
abdominal peri-hepatic abscess, and antibiotic therapy
was restarted (piperacillin/tazobactam (4 g twice a day),
gentamycin (a single injection), and vancomycin (one
injection at each hemodialysis session). By day 36, our
patient became afebrile and a third CT scan showed
regression of the peri-hepatic fluid collection. Antibiotic
therapy was again stopped on day 41, after a second 15-
day course.
O nt h ed a yt h ea n t i b i o t i ct h e r a p ys h o u l dh a v eb e e n
stopped, our patient had necrotic purpura eruptions on
the external sides of his feet, knees, and elbows (Figure 2).
Concomitant with the purpuric eruptions, he also pre-
sented with arthralgia and macroscopic hematuria, but
remained afebrile. Arthralgia was bilateral, and located in
t h ej o i n t sn e a rt h ep u r p u r i ce r u p t i o n s .H e m a t u r i aw a s
asymptomatic, and was associated to either other urinary
signs, or intra-vesical clotting. This new flare was accom-
panied by systemic inflammatory response syndrome and
elevated C-reactive protein level (124 mg/L; normal values
< 3 mg/L), and a new empirical antibiotic therapy was
initiated, including intravenous gentamycin, ceftriaxone,
and valaciclovir. Vancomycin was continued. An
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Figure 1 Timing of administration of various antibiotics and occurrence of signs related to Henoch-Schönlein purpura. *Skin biopsy.
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Page 2 of 6echocardiograph showed no signs of endocarditis. Blood
cultures, urine analysis, as well as polymerase chain reac-
tion testing for herpes simplex virus 1 (HSV1), HSV2, and
varicella zoster virus (VZV), and serology for HSV1,
HSV2, VZV, Epstein-Barr virus (EBV), human herpesvirus
6 (HHV6), human herpesvirus 8 (HHV8), cytomegalovirus
(CMV), hepatitis B virus (HBV), hepatitis C virus (HCV),
human immunodeficiency virus (HIV), parvovirus B19,
rickettsia, and Lyme disease, did not show any evidence of
recent viral, bacterial, or fungal infections. Differential
diagnostic investigations included tests for anti-nuclear
antibodies, cryoglobulin, cryofibrinogen, complement
dosage, protein electrophoresis, immunoglobulin dosage;
results were positive for isolated anti-nuclear antibody (1/
200, with no specificity), and increased circulating polyclo-
n a lI g Al e v e l( 4 . 7 1g / L ;n o r m a lv a l u e s :0 . 8 8t o4 . 1g / L ) .
Skin biopsies, performed four days after the eruptions,
showed leucocytoclastic necrotic vasculitis of the dermal
capillaries (Figure 3), with neutrophils and lymphocytes in
and around the blood vessels and intra-vascular fibrin
thrombi, all of which are characteristic features of vasculi-
tis. Immunofluorescence examination showed IgM and C3
deposits in the dermal capillary walls.
On day 53 after admission, that is, 12 days after the
first eruption occurred and after antibiotic therapy was
restarted, our patient presented with arthritis of the
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Figure 2 Image of the first necrotic purpura eruption on the feet (A), elbows (B), and knees (C).
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Page 3 of 6right knee and left elbow. Arthritis regressed sponta-
neously within 48 hours, and no articular puncture was
performed.
On day 58 after admission, he then presented with a
second purpuric eruption of both legs, associated with
arthralgia and macroscopic hematuria. All
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Figure 3 (A, B) The second biopsy (performed a few hours after the second purpuric eruption), showing dermal leucocytoclastic
vasculitis with eosinophils deposits suggestive of vancomycin-induced Henoch-Schönlein purpura. #Peri-vascular inflammatory cells;
*dermal capillaries.
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he was still receiving antibiotics at that time, so that
antibacterial therapy was interrupted. A full-body CT
scan showed no more abscess and no adenopathy, but
ascitis, which on puncture produced a sterile fluid. A
second skin biopsy was performed on the day the pur-
pura appeared. It showed the same leucocytoclastic der-
mal vasculitis with eosinophils, but vascular IgA and C3
deposits were found with immunofluorescence imaging
(Figure 3).
After antibiotic therapy was stopped, our patient
finally recovered entirely with disappearance of purpura,
arthritis and hematuria, and has not relapsed after a fol-
low-up period of eight months.
Discussion
HSP is a small-vessel systemic vasculitis characterized by
vascular wall deposits of immune complexes containing
mainly IgA. It can affect the skin, gut, and glomeruli
vessels, and is often associated with purpura, abdominal
pain, hematuria, and arthralgia or arthritis [1]. HSP is
the most common vasculitis in childhood, but can also
occur in adults [1].
Diagnostic criteria for HSP in children have been
recently validated as an association between the pre-
sence of purpura in a lower limb plus one of the follow-
ing four criteria: (1) abdominal pain, (2) histopathology
(that is, IgA), (3) arthritis or arthralgia, and (4) renal
involvement [2].
In our patient, concomitant occurrence of purpuric
lesions, arthritis, macroscopic hematuria, and an exhaus-
tive immunological exploration with negative results
confirmed the diagnosis of HSP. Consistent with this
diagnosis, his plasmatic IgA dosage was elevated.
A very surprising finding was the involvement of the
kidney in our patient with end-stage renal disease. The
chronology was clearly suggestive of HSP, with, macro-
scopic hematuria occurring concomitantly to each new
purpuric eruption, and disappearing within a few days.
However, as he was already under hemodialysis, we
were not able to fully evaluate the severity of the renal
involvement of the vasculitis in our patient.
In our patient, the first skin biopsy, performed several
days after the purpuric eruption, showed leucocytoclas-
tic vasculitis and IgM deposits (by immunofluorescence)
(Figure 3). Specific leucocytoclastic vasculitis of the skin
is a main symptom of HSP [1]. It is classically associated
with IgA deposits, but might also be associated, as in
our patient, with IgM deposits, especially when a biopsy
is performed later, and when the kidney is involved [3].
Indeed, the second biopsy, performed shortly after the
eruption, showed IgA deposits (by immunofluores-
cence), which confirmed HSP. Consistent with an aller-
gic mechanism, optical microscopy showed the presence
of eosinophilic polynuclear cells in the inflammatory
infiltrate.
The pathophysiology of HSP has not been totally elu-
cidated, but may be related to the production of abnor-
mally glycosylated IgA, which is not sufficiently cleared
by the liver and leads to the formation of IgA macromo-
lecules that accumulate in the circulation, and subse-
quently become deposited in the vessel walls causing
vasculitis [1]. Most cases of HSP are primary, but some
episodes can be related to an identified etiology, such as
infection, medication [4], or neoplasia [1].
Our patient had no history of HSP. Thus, it was prob-
ably secondary to his recent medical condition. An
infectious cause was unlikely as our patient had no fever
at the time of the first cutaneous eruption; no bacterial,
fungal or viral infection was found, although extensive
explorations were made, and the purpuric eruption
relapsed while our patient was receiving an antibiotic
therapy and the intra-abdominal abscess was well con-
trolled on the CT scans. Further, purpura appeared after
antibiotic therapy initiation and disappeared after anti-
biotic therapy withdrawal. Finally, eosinophils were
found in skin biopsies.
From the literature, drugs that have already been asso-
ciated with HSP are clarithromycin, carbidopa, cytara-
bine, enalapril/lisinopril, ciprofloxacin, acetylsalicylic
acid, cocaine, acetyl cholinesterase inhibitors, carbama-
zepine, and streptokinase [1].
In our patient’s case, the evolution of HSP was
strongly linked with vancomycin: both attacks occurred
about 15 days after vancomycin treatment was started,
and after vancomycin was stopped the evolution of HSP
stopped and our patient was cleared of HSP. In the lit-
erature, vancomycin-induced vasculitis has been
reported to occur from 1 to 27 days after the start of
vancomycin therapy [4-9].
According to a French causality assessment method
for unexpected or toxic effects of drugs [10], chronologi-
cal evolution is very suggestive (first attack 16 days after
treatment with vancomycin was started, aggravation
after reintroduction, and then regression of symptoms
with no more HSP attacks after vancomycin was
stopped) when there is no evidence of other possible
etiologies.
Several cases of vasculitis following vancomycin treat-
ment have been reported in the literature: five cases of
isolated leucocytoclastic cutaneous vasculitis [5-8] and
one case of lupus-like syndrome [9]. To the best of our
knowledge, only one case of HSP linked to vancomycin
has been described previously [4]. In that case, a patient
treated with vancomycin with a staphylococcal chest
infection presented with HSP and histologically proven
acute interstitial nephritis. As he had preserved renal
function, the interstitial nephritis was associated with
Bataille et al. Journal of Medical Case Reports 2012, 6:106
http://www.jmedicalcasereports.com/content/6/1/106
Page 5 of 6oliguric acute renal failure. The authors hypothesized
that either an anaphylactic reaction or a staphylococcal
glycoprotein release had initiated HSP.
No other cases were found in the French Pharmacov-
igilence database using the keywords HSP, vancomycin,
or teicoplanin. Interestingly, Marshall et al.r e p o r t e d
induced vasculitis cross-reactivity between teicoplanin
and vancomycin [7].
Conclusions
We report only the second case of vancomycin-induced
Henoch-Schönlein purpura that involved the skin, joints,
and kidneys. Diagnosis was made possible by the combi-
nation of specific clinical and histological findings, and
in particular the timing of events with regard to the
introduction and withdrawal of glycopeptides. This is a
rare, maybe under-diagnosed, but serious adverse event
that needs to be considered and if suspected, should
lead to prompt discontinuation of glycopeptides.
This case has been registered as French Pharmacovigi-
lence case no. MA20110866; Base Nationale de
Pharmacovigilance.
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